EHC
Encompass Health Corporation
EHC has slightly lower modeled downside risk, despite its lower overall score.
LLY
Eli Lilly and Company
LLY has the edge over EHC overall, supported by stronger fundamentals and stronger modeled upside.
EHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Healthy |
EHC's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
EHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 18x | $112 | -20% |
| Forward | 21x | $141 | — |
| Fair | 22x | $139 | -1.3% |
| Current | 22x | $141 | — |
| Expensive | 24x | $157 | +11% |
Historical ranges are pointers, not guarantees.
EHC has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
EHC Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for EHC, with profitability improving.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over EHC on the outlook, with more favorable valuation expectations.
EHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.72 | +4.9% |
| Q3 2026 | $6.40 | +21% |
| Q2 2026 | $6.14 | +20% |
| Q1 2026 | $5.99 | +24% |
| Q4 2025 | $5.54 | +24% |
| Q3 2025 | $5.29 | +28% |
| Q2 2025 | $5.11 | +30% |
| Q1 2025 | $4.84 | +31% |
| Q4 2024 | $4.46 | +29% |
EHC's earnings per share have climbed steadily: $6.40 over the past year, up 21% from the year before, and higher year over year for 13 quarters in a row.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over EHC on earnings, with stronger typical year-over-year growth.
EHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6B | +8.9% |
| Q2 2026 | $1.6B | +9.6% |
| Q1 2026 | $1.6B | +9% |
| Q4 2025 | $1.5B | +9.9% |
| Q3 2025 | $1.5B | +9.4% |
| Q2 2025 | $1.5B | +12% |
| Q1 2025 | $1.5B | +11% |
| Q4 2024 | $1.4B | +13% |
EHC's revenue has grown year over year for 13 quarters in a row: $1.6B last quarter, up 8.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +1.4 points |
| Q2 2026 | 18% | +0.3 points |
| Q1 2026 | 19% | +0.7 points |
| Q4 2025 | 18% | +1.8 points |
| Q3 2025 | 16% | +1 points |
| Q2 2025 | 18% | +1.2 points |
| Q1 2025 | 18% | +2.6 points |
| Q4 2024 | 17% | +1.3 points |
EHC's operating margin was 18% last quarter, up 1.4 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over EHC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over EHC on profitability, with a higher operating margin.
EHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $127.5M | +52% |
| Q2 2026 | $62.3M | -45% |
| Q1 2026 | $150.7M | +20% |
| Q4 2025 | $116.7M | +46% |
| Q3 2025 | $83.7M | -30% |
| Q2 2025 | $113.3M | +87% |
| Q1 2025 | $125.5M | +26% |
| Q4 2024 | $80.1M | +$101.7M |
EHC generated $457M in free cash flow over the past year, up 14% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
EHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -300K shares |
| 1 year | -2.5% | -2.6M shares |
| 3 years | -1.7% | -1.7M shares |
| 5 years | -0.5% | -500K shares |
| Available history | +0.3% | +300K shares |
EHC has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $57.9M |
| Q2 2026 | $74.2M |
| Q1 2026 | $71.6M |
| Q4 2025 | $76.3M |
| Q3 2025 | $24.9M |
| Q2 2025 | $24.7M |
| Q1 2025 | $32.1M |
| Q4 2024 | $7.5M |
EHC spent $280M buying back its own shares over the past year, about three times what it spent the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
EHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 1.8x | Healthy |
| Q3 2025 | 1.8x | Healthy |
| Q2 2025 | 1.8x | Healthy |
| Q1 2025 | 1.9x | Healthy |
| Q4 2024 | 2.1x | Moderate |
EHC's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over EHC on leverage, with a lower net debt burden relative to earnings.
EHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 72.7 | Overbought |
| Stochastic | 88.7 | Overbought |
EHC's weekly RSI is 73 (overbought) and its Stochastic is 89 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
EHC PE vs Healthcare Sector
| Metric | EHC | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 26x | 15% below |
| PE % | 53 | 29 | 24 pts above |
EHC has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
EHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $129.1 | 9.1% above |
| 20 week MA | $122.0 | 15% above |
| 50 week MA | $111.1 | 27% above |
| 100 week MA | $111.2 | 27% above |
| 200 week MA | $93.1 | 51% above |
EHC is in an uptrend: it's above all five of its weekly moving averages, and 51% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
EHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $55.5 | $65.7 | +19% |
| 2021 | $65.7 | $51.0 | -22% |
| 2022 | $51.0 | $59.3 | +16% |
| 2023 | $59.3 | $66.7 | +13% |
| 2024 | $66.7 | $93.6 | +40% |
| 2025 | $93.6 | $107.5 | +15% |
| 2026 YTD | $107.5 | $140.8 | +31% |
EHC has finished higher in five of the last six years. It's up 31% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over EHC on returns for 2026, with the stronger performance.